| Literature DB >> 34331594 |
Rupali S Bhadale1, Vaishali Y Londhe2.
Abstract
Microneedles (MNs) are minimally invasive tridimensional biomedical devices that bypass the skin barrier resulting in systemic and localized pharmacological effects. Historically, biomaterials such as carbohydrates, due to their physicochemical properties, have been used widely to fabricate MNs. Owing to their broad spectrum of functional groups, carbohydrates permit designing and engineering with tunable properties and functionalities. This has led the carbohydrate-based microarrays possessing the great potential to take a futuristic step in detecting, drug delivery, and retorting to biologicals. In this review, the crucial and extensive summary of carbohydrates such as hyaluronic acid, chitin, chitosan, chondroitin sulfate, cellulose, and starch has been discussed systematically, using PRISMA guidelines. It also discusses different approaches for drug delivery and the mechanical properties of biomaterial-based MNs, till date, progress has been achieved in clinical translation of carbohydrate-based MNs, and regulatory requirements for their commercialization. In conclusion, it describes a brief perspective on the future prospects of carbohydrate-based MNs referred to as the new class of topical drug delivery systems.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34331594 PMCID: PMC8325649 DOI: 10.1007/s10856-021-06559-x
Source DB: PubMed Journal: J Mater Sci Mater Med ISSN: 0957-4530 Impact factor: 3.896
Fig. 1Cumulative publications on the microneedle drug delivery system. The analysis was done by the PubMed database using the search term “microneedle drug delivery” [98]
Description of criteria listed for the selection of records for review
| Sr. No. | Criteria | Description |
|---|---|---|
| Designing, evaluation, and safety of microneedle | • Was there a clear description of the fabrication, biopolymer used, and compatibility of carbohydrate-based microneedle? • Was there a clear description of the evaluation and application of carbohydrate-based microneedle? | |
| Preclinical and clinical presence | • Was a complete preclinical and clinical study described? • Was there a relevant conclusion to the study? |
Fig. 2PRISMA flowchart for the records reviewed [9]
Fig. 3Schematic representation of a microneedle inserted into the skin
Fig. 4Schematic representation of MNs A MN assembly (a) in-plane and (b) out-of-plane. B The design of out-of-plane MNs is defined as (a) hollow and (b) solid. C Microarrays are (a) cylinder-shaped, (b) conical, (c) pyramidal, (d) and (e) pentagonal-based pointy and tapered tip, respectively
Fig. 5Different types of MNs according to the drug delivery approaches a solid, b coated, c dissolving, d hollow, and e hydrogel-forming MNs
Drug delivery approaches and fabrication methods for different types of microneedles with delivery efficacy
| Systems | Approaches | Fabrication techniques | Delivery efficiencya | References | ||
|---|---|---|---|---|---|---|
| Drug loading | Sustain release | Molecular range | ||||
| Solid MNs | Poke with patch | Vapor deposition, Dry etching, Wet etching, Micro-stereolithography, Laser cutting, laser ablation, Photolithography, Micro-molding, melt casting, and Metal electroplating, 3D printing | + | + | ++ | [ |
| Coated MNs | Coat and poke | Dipping, Spraying | + | + | ++ | [ |
| Dissolving MNs | Poke and release | Photolithography, Deep X-ray lithography, drawing lithography, Micro-molding and melt casting, Droplet born air blowing, Two-photon polymerization, 3D printing | +++ | +++ | ++ | [ |
| Hollow MNs | Poke and flow | +++ | +++ | ++ | [ | |
| Hydrogel-forming MNs | Poke and release | Photolithography, Deep X-ray lithography, Dry etching, Wet etching, Metal electroplating, drawing lithography, Two-photon polymerization | +++ | +++ | +++ | [ |
aLow- +, Moderate- ++, High- +++
Fig. 6Illustration of the mechanical properties of MNs. a Axial force test. b Transverse force test. c Base-plate strength and flexibility tests. d Microneedle-insertion measurement by staining
Failure force after an axial force load of carbohydrates
| Composition of MN | Failure force | Reference |
|---|---|---|
| Hyaluronic acid (HA) | ≥0.05 | [ |
| 0.4–0.6 | [ | |
| 0.18 | [ | |
| HA with Epidermal growth factor | 0.63–0.78 | [ |
| Sodium hyaluronate with Enterovirus | ≥0.08 | [ |
| Lysozyme loaded HA | 0.20 | [ |
| Methacrylate HA | ≥0.15 | [ |
| Sodium alginate | Transverse force failure 0.04 | [ |
| Chitosan | ≥0.2 | [ |
| Magnetic graphene quantum dots loaded Chitosan | ≥0.16 | [ |
| Carboxymethyl Cellulose | 0.5–0.8 | [ |
Merits and demerits of dissolvable, biodegradable, and swellable carbohydrate-based microneedles [54]
| Microneedle design | Merits | Demerits |
|---|---|---|
| Dissolvable Microneedle | • Allow fast drug release as the rate of dissolution is increased • Encapsulation or coating can improve drug loading • Precise drug loading can be achieved • Generally used for sustained drug release | • A patch can not be detached before the complete dissolution of microneedles |
| Biodegradable Microneedle | • Encapsulation or coating can improve drug loading • Precise drug loading can be achieved • Attachment of Drug reservoir is allowed | • After few days of degradation, polymer residue can be detected in the skin |
| Hydrogel forming/Swellable Microneedle | • After removal, Smoothness prevents reinsertion • After few days of degradation, polymer residue can’t be detected in the skin • If necessary, treatment can be stopped | • Inadequate drug loading • Bioactivity of a drug may hamper due to cross-linking of the polymer |
Summary of carbohydrate-based MNs for drug delivery
| Carbohydrate(s)and auxiliary agent | Active pharmaceutical ingredient (API) | Delivery efficiency | Findings | Reference |
|---|---|---|---|---|
| Maltose | Ascorbate-2-glycoside | Completely dissolves within 5 mins after application, in vivo | Short-term safety after insertion in healthy human skin and notable disposability | [ |
| Maltose | Doxorubicin | Release the drug till 24 h, in vitro | Enhancement in permeation after piercing into human cadaver skin | [ |
| Hyaluronic acid (HA) | All trans-retinoic acid, Tetanus toxoid, Ovalbumin, and diphtheria toxoid | Completely dissolves within 120 mins after application, in vivo | Better stability, induced immunological responses after 12month of storage | [ |
| HA | Ovalbumin and adenovirus vector | Completely dissolves within 60 mins after application, in vivo | Improved response when compared with conventional vaccination | [ |
| HA | Fluorescein isothiocyanate-dextran | Microarrays completely dissolve within 120 mins after piercing, in vivo and continuous dissolution of a baseplate seen after application of 7 h. | Enhanced permeability of high molecular macromolecule ass | [ |
| HA | Insulin | Completely dissolves within 60 mins after application, in vivo | A dose-related hypoglycemic effect akin to a hypodermic needle | [ |
| HA | Green tea extract | Release the drug till 72 h, in vitro | Diminution of microbial development (gram-negative and positive) at the infected area | [ |
| HA | Enterovirus 71 virus-like particles | Completely dissolves within 2 mins after application, in vivo | API remained stable during fabrication, an increase in immunization by giving protection against hand-foot and mouth disease when compared with intramuscular injection | [ |
| HA | Igg (Immunoglobulin G) | Dissolves within 10 mins after application, ex-vivo in human skin | Principal Protein was conserved, and its tertiary structure unchanged | [ |
| HA with Amylopectin | Niacinamide and ascorbic acid | Dissolves within 8 h after application, ex-vivo in porcine skin | Applicable in cosmetic owing to its anti-oxidant activity | [ |
| HA | Tuberculin purified derivatives | 80% of dissolution /diffusion of MNs seen within 8 h. | Potential to be used for diagnosis of tuberculosis | [ |
| HA | Adenosine | – | Demonstrated improvement or Similar outcomes compared to cream | [ |
| HA with gold (Au) nanocages loaded | Doxorubicin | Dissolves within 5 mins after application, in vivo | Applicable for the devastation of superficial skin tumor | [ |
| HA | Dermatophagoids farinae extract | Twice a week for 4weeks, extended-release formulation | Potential as allergen-specific immunotherapy | [ |
| HA | Live attenuated Bacille Calmette-Guerin bacillus | Diffusion of the drug was observed in 6 h after application of MNs | Applicable for effective vaccine delivery when compared with the conventional dosage form | [ |
| HA | Β-3-Adrenoceptor agonist and thyroid hormone | Completely dissolves within 2 mins after application, ex-vivo in porcine skin | The decrease in body fat and weight in obese mouse models | [ |
| HA | Pegylated gold nanorod and doxorubicin | – | [ | |
| HA | Ascorbic acid 2-glucoside | Approximately, 75% of dissolution of MNs seen at the end of 20 mins. | The dose and activity of the Drug was sustained after e-beam sterilization | [ |
| HA with Nanostructured lipid carriers using Compritol, labrafil | Nile red | Sustained release of Nile red | Effective delivery of hydrophobic component | [ |
| HA and carboxymethyl cellulose + Amylopectin | Rhodamine B | Dissolves within 8 mins 10secs after application, ex-vivo in porcine skin | Enhanced permeability of Drug | [ |
| HA and carboxymethyl cellulose + Amylopectin | Rhodamine B Niacinamide | Approximately, 40% of dissolution of MNs seen at the end of 10 mins. | Increased permeability, which can be applied for cosmetic | [ |
| HA + 3-aminophenyl boronic acid-modified alginate | Insulin | Sustained release of Insulin achieved, in vivo | Initiation of a maintained hypoglycemic effect in diabetic mice | [ |
| HA cross-linked with N, N-methylene bis (acrylamide) + nanoparticles of dextran | Anti-PD1 immunotherapy | A synergistic effect was observed, in vivo | Increased inhibition of tumor growth over the intratumoral injection | [ |
| Sodium chondroitin sulfate + poly (vinyl pyrrolidone), lyotropic liquid crystal | Sinomenine hydrochloride | Sustained release of Sinomenine hydrochloride achieved to some extent, in vivo | Enhanced permeability of Drug with the maintained release, which can be applied to adjuvant arthritis model rats | [ |
| Sodium chondroitin sulfate | Capsaicin | Completely dissolves within 20 mins after application, in vitro | Improved efficiency over a topical formulation which exhibits rapid local analgesic action | [ |
| Sodium chondroitin sulfate | Insulin | fully-loaded tip and partially loaded tip with Insulin exhibit similar dissolution rate | Better efficiency of the Drug, fully-loaded tip exhibit extreme effect of the Drug detected at 1.7 ± 0.2 h and 1.5 ± 0.2 h for the partially loaded tip | [ |
| Carboxymethyl cellulose | Recombinant human adenovirus type 5 vector encoding HIV-1 gag | Rapid dissolution was seen, in vivo | Long-lived antigen-specific cell genesis on the mucosal surface to employ local immunosurveillance, which supplies the first-line defense against pathogens | [ |
| Carboxymethyl cellulose | Valproic acid | At the end of 90 mins, drug release enhanced due to dissolution of MNs | Enhances hair growth with high precision over the topical system | [ |
| Carboxymethyl cellulose | (Anti-TNF-alpha-Ab)-HA conjugates | Approximately, 60% of dissolution of MNs seen at the end of 20 mins after application | Applicable to a wide array of inflammatory skin diseases | [ |
| Carboxymethyl cellulose + Amylopectin | Rhodamine Ascorbic acid | Approximately, 30% of dissolution of MNs seen at the end of 8 mins after application, ex-vivo in porcine skin | 3-fold permeability enhancement of rhodamine and 6-fold rise anti-oxidant activity of ascorbic acid over the topical application | [ |
| Carboxymethyl cellulose + double hydroxides nanoparticles | Ovalbumin | Completely dissolves within 1 mins after application in skin | Efficacy enhancement was perceived over the subcutaneous injection | [ |
| Carboxymethyl cellulose | Immediately dissolved after application, in vivo | The in vivo study revealed the maximum concentration of lactic acid in pig and rat skin | [ | |
| Carboxymethyl cellulose + hydroxymethyl cellulose | Donepezil hydrochloride | Approximately, 80% of dissolution of MNs seen at the end of 60 mins after application, ex-vivo in porcine skin | Enhancement in response over the oral route for Alzheimer disease | [ |
| Carboxymethyl cellulose + poly (vinyl alcohol) as a backing membrane | Etonogestrel microcrystals | Approximately, 70% of MNs dissolved at the end of 60 mins after application, in vivo | Tip loaded MNs does not affect mechanical properties and more consistent plasma level over the intradermal injection | [ |
| Carboxymethyl cellulose + poly (methyl vinyl ether co-maleic anhydride) | Lidocaine hydrochloride | Completely dissolves within 5 mins after application in rat skin | A stable formulation for 3months and higher dissolution over the commercial cream but less efficiency | [ |
| Chitin | Purified protein derivative, containing a mixture of antigen | – | The definite results approved the potential application of Chitin MNs for diagnosis | [ |
| Chitosan+ Trehalose, poly (vinyl alcohol)/ poly (vinyl pyrrolidone) | Luteinizing hormone-releasing hormone analogs, goserelin | Sustained release of drug for 28days | Significantly applied for the treatment of androgen-deprivation, castration level was sustained for 14days | [ |
| Chitosan+ β-Sodium glycerophosphate and hydroxypropyl β-cyclodextrin | Levonorgestrel | Approximately, 57% of MNs dissolved at the end of 120 mins after application | Alike pharmacokinetic parameters over the oral dose with steady plasma concentration | [ |
| Chitosan+ Poly (vinyl alcohol) + Polyvinylpyrrolidone as supporting array | Ovalbumin | Controlled release of drug | Increased efficiency of the low-dose Drug when compared with intramuscular injection | [ |
| Chitosan+ Magnetic graphene quantum dots + Polyethylene glycol | Lidocaine hydrochloride | Microarrays dissolved within 5 mins after application | Enhanced release from 25.7 to 96.4% due to iontophoresis | [ |
| Starch+ Gelatine | Bovine serum albumin | Sustained release | Sustained action for 8days | [ |
| Starch | Insulin | Immediately dissolved after application | Substantial pharmacological action distributed the whole Drug within 5 mins | [ |
| Hydroxyethyl starch (tip)+ Sodium chondroitin sulfate (needle) | Hepatitis B surface antigen (tip) | 100% dissolution was achieved after application | Similar immunoreaction as a marketed vaccine, antigenicity was reserved at 37 and 45 °C | [ |
| Pullulan | FITC-BSA and insulin | Completely dissolves within 10 mins after application in skin | The efficiency of drug administration using MNs was more effective than the oral route; these MNs could replace the current method for protein/peptide delivery | [ |
| Dextran | Poly-L-arginine | Approximately, 75% of MNs dissolved after application in rat skin | Efficacy of Drug depends upon dosage regimen, also can be a substitute to skin allergy device | [ |
list of active and completed clinical trials [91]
| Carbohydrate | Condition | Identifier | Titles | Year | Status |
|---|---|---|---|---|---|
| HA | Crow’s Feet Wrinkles | NCT02497846 | TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow’s Feet Wrinkles | 2016 | Completed |
| HA | Psoriasis | NCT02955576 | Microneedle Patch for Psoriatic Plaques | 2017 | Active |
| HA | Vitiligo - Macular Depigmentation | NCT02660320 | Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion for Repigmenting in Vitiligo Skin (Dermabrasion) | 2018 | Active |
| Starch | Primary Axillary Hyperhidrosis | NCT03054480 | Fractional Micro-Needle Radiofrequency and Botulinum Toxin A for Primary Axillary Hyperhidrosis | 2017 | Completed |
| Starch | Primary Axillary Hyperhidrosis | NCT02823340 | Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis | 2016 | Active |